Trust Co. of Toledo NA OH Has $1.40 Million Holdings in Medtronic PLC $MDT

Trust Co. of Toledo NA OH cut its stake in shares of Medtronic PLC (NYSE:MDT) by 1.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 16,069 shares of the medical technology company’s stock after selling 283 shares during the period. Trust Co. of Toledo NA OH’s holdings in Medtronic were worth $1,401,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the stock. Brighton Jones LLC increased its holdings in shares of Medtronic by 1,368.0% in the fourth quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock worth $3,194,000 after acquiring an additional 37,265 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of Medtronic by 41.1% in the first quarter. GAMMA Investing LLC now owns 15,882 shares of the medical technology company’s stock worth $1,427,000 after acquiring an additional 4,626 shares in the last quarter. CX Institutional increased its holdings in shares of Medtronic by 8.0% in the first quarter. CX Institutional now owns 7,702 shares of the medical technology company’s stock worth $692,000 after acquiring an additional 568 shares in the last quarter. Simon Quick Advisors LLC increased its holdings in shares of Medtronic by 51.2% in the first quarter. Simon Quick Advisors LLC now owns 7,801 shares of the medical technology company’s stock worth $701,000 after acquiring an additional 2,641 shares in the last quarter. Finally, Fifth Third Bancorp increased its holdings in shares of Medtronic by 3.8% in the first quarter. Fifth Third Bancorp now owns 198,673 shares of the medical technology company’s stock worth $17,853,000 after acquiring an additional 7,205 shares in the last quarter. 82.06% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director William R. Jellison purchased 2,500 shares of the firm’s stock in a transaction on Monday, August 25th. The stock was purchased at an average cost of $92.37 per share, for a total transaction of $230,925.00. Following the completion of the purchase, the director directly owned 5,000 shares in the company, valued at $461,850. This trade represents a 100.00% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Harry Skip Kiil sold 8,605 shares of the firm’s stock in a transaction that occurred on Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a total value of $788,045.90. Following the completion of the transaction, the executive vice president owned 35,615 shares of the company’s stock, valued at approximately $3,261,621.70. This represents a 19.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.26% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on MDT. Morgan Stanley restated an “overweight” rating and issued a $107.00 price target (up from $98.00) on shares of Medtronic in a report on Tuesday, July 15th. Argus increased their price target on Medtronic from $105.00 to $115.00 and gave the stock a “buy” rating in a report on Tuesday, August 26th. Daiwa Capital Markets increased their price objective on Medtronic from $101.00 to $104.00 and gave the stock a “buy” rating in a report on Friday, September 12th. Wall Street Zen downgraded Medtronic from a “buy” rating to a “hold” rating in a report on Friday, October 3rd. Finally, William Blair upgraded Medtronic to a “hold” rating in a report on Friday, July 11th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Medtronic has an average rating of “Moderate Buy” and a consensus price target of $102.41.

Medtronic Stock Down 1.0%

MDT stock opened at $95.52 on Friday. The company has a quick ratio of 1.50, a current ratio of 2.01 and a debt-to-equity ratio of 0.54. The business has a 50 day moving average price of $93.56 and a two-hundred day moving average price of $88.74. The company has a market cap of $122.52 billion, a price-to-earnings ratio of 26.31, a P/E/G ratio of 2.54 and a beta of 0.78. Medtronic PLC has a twelve month low of $79.29 and a twelve month high of $99.37.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share for the quarter, beating analysts’ consensus estimates of $1.23 by $0.03. The firm had revenue of $8.58 billion during the quarter, compared to the consensus estimate of $8.37 billion. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.The business’s revenue was up 7.7% compared to the same quarter last year. During the same period last year, the company earned $1.23 earnings per share. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. Analysts anticipate that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 17th. Shareholders of record on Friday, September 26th will be paid a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a yield of 3.0%. The ex-dividend date is Friday, September 26th. Medtronic’s dividend payout ratio (DPR) is currently 78.24%.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.